

## Colorado COVID-19 Vaccine Screening and Administration Form



Please	e print nea	tlv in	capital	letters	as sho	own in	the ex	kample	: Dloos	o ancu	or al	II aug	stions (	as coi	mnlet	oly as									
E	<u>, , , , , , , , , , , , , , , , , , , </u>	M	Γ <u>΄</u> Τ		E	1	2	3	possi	ble.			ink to				In	e adn this d				ecord	is on the	e rever	se side
Dleas	e comr	lete	AII :	the ir	oform	ation	, bal	OW 30	3 2 C C L I	ratoly	/ 35	noss	ible	If w	) II 2	re co	mpl	otir	na tí	aic f	orn	n for	VOUR	mino	NT.
Please complete ALL the information below as accurately as possible. <b>If you are completing this form for your m</b> child, do not use nick-names or abbreviations, except where allowed. All information will be kept confidential.																<b>,</b> 1									
Patie	nt/Child	Last I	Name											Pati	ent/	Child	First	Nan	ne						<u>M.I.</u>
Date	of Birth						_	Age	(years)	Age (	mont	hs)		Pa	tien	t/Rep	reser	ntati	ve D	aytiı	me l	Phone	e Numb	er	
			_]/														<b>ไ-</b> [				<b> -</b>				
M If und	M er 18 year	D D			Y Y	′ Y							Par	rent l	_ast N	lame					. –				
	please	, <u></u>		Jerian																					
Addr	ess			-	_					_	•					-	-	•	-	•	Ap	t. Nu	mber		
, au																									
City		County													Stat	State									
													<u> </u>										] [		
Zip C	ode			E-n	nail Ad	ddres	 S															_	J L		
•																									
Gender Identity F M Transgender Female/Feminine Transgender Male/Masculine Non-Binary Un-specified Decline to Provide														wide											
	ou Hispa								that app		350110		200771103	Jeann			Jiliai y			эрсс			Decime		71140
	s No								n/Alask		ive	∏Bla	ack, Af	rican	Ame	rican		Γ	٦ <sub>01</sub>	her		□De	cline to	Provid	e
						Asi	ian					☐ Na	tive Ha	awaii	an/Pa	acific I	slande	er [	□w	hite					
Healt	h Insura	nce		(OPT	IONAL-	INSUR	ANCE	NOT F	REQUIRE	D FOR	VAC	CINAT	ΓΙΟΝ)			Insu	ance	Pol	icy N	lumt	er				
Ме	dicaid	Medi	care	Kaise	er Perm	anent	e Uni	ted He	althcare 7	e Oth	ner Pr Г	ivate	No	Insur	ance										
f you l	nave alread	ly rece	ived yo	our Prim	nary Dos	se(s) of	a COV	ID-19 v	accine, p	lease t	ell us	which	vaccine	e(s) yo	u rece	eived a	nd the	date(	(s) of	vacci	natio	n.	· · · · ·		
ose(s)	received:	Dose 1	1: Vacci	ine Brar	nd		Vacci	ination	Date	/_	/_		_   Dos	e 2: V	accine	e Branc			_ Vac	cinati	on D	ate	/	/_	
f you l	nave alread	ly rece	ived m	ore tha	n two (2	2) dose	s of a (	COVID-1	9 vaccin	e, plea	se tel	l us wh	nich add	litiona	l dose	(s) you	receiv	ed, th	ne vad	cine(	s), ar	nd the	date(s) o	f vaccir	nation.
Additio	onal Dose r	eceive	d for H	igh Risk	Condit	ions : \	/accine	e Brand		Va	ccina	tion Da	ate	/_		/	_								
Booste	r Dose: Va	cine B	rand		Vaco	ination	) Date				Ada	litiona	l Booste	er Dos	e: Vac	cine B	and			Vacci	natio	n Date	·	/	/
Healt	h Screening	Questi	ions																				Yes	No	Don't Know
1.	Are you o	r your	child si	ck toda	y or hav	e a fev	er?																		
2.	Have you	or you	r child I	had an a	allergic	reactio	n to po	olysorba	ite, polye	ethylene	glyc	ol, or a	a previo	us dos	e of C	OVID-1	9 vacc	ine?							
3.	Have you	or you	r child (	ever ha	d a serio	ous alle	rgic re	action (	(anaphyla	axis) to	anoth	er vac	cine or a	any in	jectal	ole med	lication	n?							
4.	Have you or your child had severe allergic reaction (anaphylaxis) to foods, pets, venom, environmental or oral medications?																								
5.	Do you or	your c	hild ha	ve a ble	eding d	isorder	, are o	n long-t	erm aspi	rin ther	ару, с	or take	other b	olood	thinne	ers?									
6.	Have you	or your	child e	ever had	l Guillaiı	n-Barré	Syndro	ome (a t	ype of te	mporar	y seve	ere mus	scle wea	akness	) afte	r recei	ring a \	/accin	e?						
7.	Have you	receiv	ed any	dermal	fillers (	Juvade	rm®, R	estylane	e®, etc.)?	(only a	applie	s to mi	RNA vac	cines)											
8.	Do you ha	ve a hi	istory o	f blood	clots or	have r	isk fac	tors for	developi	ng bloo	d clot	s? (Jan	issen va	ccine	only,	applies	to fen	nales	ages	18-49)				$oxed{oxed}$	
9.	Do you or	your c	hild ha	ve a his	tory of	myocar	ditis o	r perica	rditis? (E	speciall	y male	es ages	s 12-29 y	years	after ı	receivir	ng a do	se of	mRNA	vacc	ine)				
10.	Do you or	-				•				,															
11.	Do you or infection		hild ha	ve a his	tory of	Multisys	stem Ir	nflamma	atory Syn	drome k	known	as MIS	S-C (in c	hildre	n) or	MIS-A (	in adul	ts) af	ter a	COVIE	)-19				
12.	Are you o	r your o	child im	munoco	omprom	ised? (S	ee add	litional o	dose sect	ion on r	ext p	age)													

06/24/2022 Continued on Next Page

Patie	ent/C									Pa	atie	ent/	Chile	d Fir	st N	Nam	e									M	\.l.							
			-						-		-					' <u>'</u>	Age	(yea	ars)	Age	(m	ontl	ns)				<u> </u>		٦٢					
Date of Birth																						Primary Dose: 1 2 3 3												
Dat	]/														Booster Dose: 1 2* □																			
Autho	rizat	ion	to A	dmi	inis	ter (	cov	/ID-	19 V	acci	ne																							
																														nd the bene				
																												ereb	oy r	elease this p	orovide	er, its	5	
employ	employees and its volunteers from any liability for any results which may occur from the administration of this vaccine.																																	
Signatu									lian/															Date				,		,				
Medica	Medical Durable Power of Attorney:Date:/																																	
	STOP: DO NOT WRITE BELOW THIS LINE-FOR CLINIC STAFF ONLY																																	
COVID	COMP WES DIN															** '																		
	T	T	1	ı	$\overline{}$	$\neg$		Publ		Clinic Name													Provider Name										1	
	0 7 3 0   X Private									H I G H L						.   A   N D   S							<u>  K</u>	C	) I	N	<u>O</u>							
Brand N	lame	(if a	vailat	le)						II ` ' ' ' '						Pfizer (Orange Cap)							r (Mar						J&J (Janssei					
∥ p∣ i	PFIZER									(ages 12 years and older) Primary Dose 0.3 ml						(ages 5 - 11 years) Pediatric Primary						Ped	atric I				0.0	(ages 18 years and older) Primary Dose 0.5 ml						
L'L'	<u>'   '</u>				. `			丄	_	Booste	er Do	ose	Γ	0.	.3 ml	Boo	and oster	d Dose	•	Ш	0.2	ml	Dose	•				0.2 r	mı	Booster Dose	_ د	0.5	i ml	
Lot Nun	nber															Moderna (blue cap/purple border)						er)	Mode	rna (£	olue c	ap/ me	igenta	ı borde	Moderna (blu	e cap/pur	ple bord	der)		
										(ages 12 years and older)						(ages 6 - 11 years)					,	Moderna (blue cap/ magenta border)   Moderna (blue cap/ ages 6 mo 5 years)   Pediatric Primary   0.25 ml												
											Primary Dose 0.5 ml						Primary Dose 0.5 ml						Dose Booster Dose ONLY 0.									).5 ml		
Date Administered											Booster Dose 0.25 ml																							
										Vial Expiration Date							Site						Administered by											
																						l												
M M D D Y Y Y Y —																							Name Title											

For vaccine administration guidance, including: timing, dosing, site selection, needle length and gauge, and administration procedures, please reference your standing orders or the CDC's Interim Clinical Considerations".

https://covid19.colorado.gov/vaccine-providers

https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

https://www.immunize.org/covid-19/

\*Additional guidance from the FDA for 2nd booster dose is as follows:

- A second booster dose of either the Pfizer-BioNTech COVID-19 Vaccine or Moderna COVID-19 Vaccine may be administered to
  individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19
  vaccine.
- A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine may be administered to individuals 12 years of age and older with certain kinds of immunocompromising conditions at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine. These are people who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise.
- A second booster dose of the Moderna COVID-19 Vaccine may be administered at least 4 months after the first booster dose of any authorized or approved COVID-19 vaccine to individuals 18 years of age and older with the same certain kinds of immunocompromise.

## \*Additional Guidance for J &J Vaccine use:

- Assess persons 18 years of age and older for vaccination with Janssen COVID\_19 Vaccine based on the following criteria:
  - mRNA COVID-19 Vaccines are preferred over Janssen COVID-19 Vaccine for primary series and booster vaccination
  - Inform all persons receiving a Janssen vaccine of the risks and symptoms of thrombosis with thrombocytopenia syndrome (TTS) in the 3 weeks after vaccination as was as the need to seek immediate care should symptoms develop.
- Janssen COVID-19 Vaccine may be offered in some situations:
  - A true contraindication to mRNA vaccines (severe allergic reaction to a previous dose or a component of the vaccine
  - The person would otherwise remain unvaccinated for COVID-19 due to limited access to mRNA vaccine
  - The person wants to receive the Janssen COVID-19 vaccine despite the safety concerns identified